HCW Biologics Inc (NASDAQ:HCWB) does about 8.94M shares in volume on a normal day but saw 1240229 shares change hands in the recent trading day. The company now has a market cap of 21.12M USD. Its current market price is $0.56, marking a decrease of -8.13% compared to the previous close of $0.61. The 52 week high reached by this stock is $2.52 whilst the lowest price level in 52 weeks is $0.28.
HCW Biologics Inc (HCWB) has a 20-day trading average at $0.5459 and the current price is -77.84% off the 52-week high compared with 102.25% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.5298 and its 200-day simple moving average is $0.9157. If we look at the stock’s price movements over the week, volatility stands at 27.28%, which decreases to 25.31% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 49.11 to suggest the stock is neutral.
The consensus objective for the share price is $3.00, suggesting that the stock has a potential upside of 81.33% over the period.
The current price level is 2.30%, 5.40%, and -39.02% away from its SMA20, SMA50, and SMA200 respectively, with the HCWB price moving below the 50-day SMA on current market day. HCW Biologics Inc (HCWB) stock is down -49.24% over the week and 23.81% over the past month. Its price is -54.42% year-to-date and -48.77% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/30/2024, with the company’s earnings per share (EPS) of -0.3 below consensus estimates by -0.15. The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year. In addition, estimates put the company’s current quarterly revenue at an average of $7M.
To reach the target analysts have set, the stock logically needs to grow 81.33 percent from here.
Outstanding shares total 36.03M with insiders holding 52.30% of the shares and institutional holders owning 3.13% of the company’s common stock. The company has a return on equity of -537.24%. The beta has a value of 1.02. Price to sales ratio is 6.03.
